Wall Street Zen downgraded Cue Biopharma (NASDAQ:CUE) from buy to hold on Saturday. The action follows the company’s August 14 second-quarter earnings report. Cue Biopharma reported a significant earnings per share miss. The company beat revenue expectations for the quarter.
CEO Shao-Lee Lin sold over $1.6 million in common stock between August 12 and August 13. Disclosures on August 15 indicated the sales covered tax obligations from vesting restricted stock units. The non-discretionary transactions occurred as the stock price rose 26% over the past week.